MOUNTAIN VIEW, Calif., Oct. 28, 2009 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it will report financial results for the third quarter ended September 30, 2009 after the NASDAQ Market closes on Tuesday, November 3, 2009.
Date: November 3, 2009 Time: 1:30 PM PT Listen via Internet: http://ir.vivus.com/ Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=39520&k=E0EBC736
Toll-free: 877-857-6173 International: 719-325-4932
A webcast replay will be available on the VIVUS web site for 30 days.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.